Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

9.3%

4 terminated/withdrawn out of 43 trials

Success Rate

84.0%

-2.5% vs industry average

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

52%

11 of 21 completed trials have results

Key Signals

12 recruiting11 with results

Enrollment Performance

Analytics

N/A
14(40.0%)
Phase 2
9(25.7%)
Phase 1
8(22.9%)
Early Phase 1
3(8.6%)
Phase 3
1(2.9%)
35Total
N/A(14)
Phase 2(9)
Phase 1(8)
Early Phase 1(3)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (43)

Showing 20 of 43 trials
NCT00760656Recruiting

Establishment of a Lifetime of Cohort of Adults Surviving Childhood Cancer

Role: collaborator

NCT06964009Phase 1Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Role: collaborator

NCT04134325Early Phase 1Active Not Recruiting

Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma

Role: collaborator

NCT02693535Phase 2Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Role: lead

NCT03546686Phase 2Active Not Recruiting

Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer

Role: collaborator

NCT06377852Phase 3Recruiting

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Role: lead

NCT04099290Recruiting

Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT06895473Phase 2Recruiting

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome

Role: collaborator

NCT06089083Recruiting

PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

Role: collaborator

NCT05912231Not ApplicableActive Not Recruiting

Ultrahypofractionation and Normal Tissue Toxicity

Role: collaborator

NCT06046014Not ApplicableCompleted

Feasibility of Expressive Writing for Body Image Distress and Anxiety Among Adolescent and Young Adult Cancer Survivors

Role: collaborator

NCT02869802Recruiting

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

Role: collaborator

NCT06795139Not ApplicableActive Not Recruiting

Pilot of a Trial Enrollment Diversity Dashboard

Role: collaborator

NCT06582849Not ApplicableCompleted

Enhanced Assistance During Radiotherapy for Unmet Essential Needs

Role: collaborator

NCT05934838Phase 1Recruiting

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Role: collaborator

NCT06469307Not ApplicableRecruiting

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Role: collaborator

NCT06907797Not ApplicableRecruiting

Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing

Role: collaborator

NCT04754399Phase 2Completed

Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Role: collaborator

NCT01184885Early Phase 1Completed

A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy

Role: collaborator

NCT03249090Not ApplicableCompleted

Electronic Patient Reporting of Symptoms During Cancer Treatment

Role: collaborator